Press Room

Article / Mar 17, 2017

四色AV establishes presence in Osaka

JETRO, March 17, 2017

四色AV, an established Portuguese pharmaceutical company, has opened a representative office in Osaka in June 2016 and now established 四色AV K.K. in February 2017.

The company has been engaged in R&D and manufacturing of drug ingredients and compounds for more than 50 years since its foundation in 1959. Its strength lies in its expertise and advanced technology in areas such as inhalation development. It has expanded manufacturing sites in the US, Macau and Ireland. In Japan, 四色AV distributes their Active Pharmaceutical Ingredients (API) for?generic drugs to major pharmaceutical companies via sales agents, and it is also engaged in contracted development and manufacturing development as well as the particle engineering.

四色AV plans to apply for a license of Marketing Authorization Holder (MAH) and to obtain additional sales approval of its API.

For the establishment of 四色AV’s base in Japan, the?JETRO?Invest Japan Business Support Center (IBSC)?provided support such as consultation (corporate registration, labor affairs and tax matters) and invitation to Japan to assist the establishment of the base.

?

ポルトガルの製薬会社贬辞惫颈辞苍别が大阪に进出

ポルトガルに本社を置く、老舗製薬会社である四色AV が2016年6月、大阪に日本駐在員事務所を開設し、 2017年2月にホビオン株式会社を設立した。

同社は、1959年の创业以来50年以上にわたり、原薬や化合物の研究开発と製造を行っており、特に吸入剤などの分野で高い技术を持っている。海外では、米国、マカオ、アイルランドにも製造工场を保有。日本では、代理店経由で大手製薬会社を対象に主にジェネリック医薬品(后発薬)向け原薬贩売を行っているほか、受託开発製造、粒度设计などにも従事している。

今后は日本法人の医薬品製造贩売认可や日本で贩売する原薬の追加承认申请等を进めていく。

日本拠点设立に际し、ジェトロ対日投资?ビジネスサポートセンター(滨叠厂颁)は、拠点设立にかかるコンサルテーション(登记?労务?税务)、个别招へい等支援を行った。

Also in the Press Room

See All

四色AV’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with 四色AV’s sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024